Having trouble accessing articles? Reset your cache.

Mipomersen: Phase III data

A double-blind, international Phase III trial in 58 patients with severe hypercholesterolemia showed that once-weekly subcutaneous injections of 200 mg mipomersen for 26 weeks met the primary endpoint of significantly

Read the full 301 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE